Utility of pharmacogenomic tests in treating pediatric depression, anxiety and ADHD
1Children's Hospital of The King's Daughters, USA.
Abstract:
Despite the scientific advancement and increasing interest in the use of pharmacogenomic tests to determine how genes interact with medications, such tests require nuanced understanding and interpretation in the treatment of pediatric depression, anxiety, and ADHD. Pharmacogenomic testing can be useful in certain populations to identify a psychotropic medication's tolerability or adverse effects. Pharmacogenomic testing cannot predict which medication will provide the best clinical response in a specific patient with a specific mental illness. Unfortunately, some commercial testing kits provide clinical guidance based on genetic tests that may not have clinical relevance in an over-simplified color-coded format which can be misleading for the patient and for the clinician. It is imperative that pediatricians understand the utility and limitations regarding the use of such tests so they can correct misinformation and provide evidence-informed care to their patients.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
